April W Armstrong
Overview
Explore the profile of April W Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
448
Citations
8268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K, et al.
Dermatol Ther (Heidelb)
. 2025 Mar;
PMID: 40048065
No abstract available.
2.
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, et al.
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40045918
Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for...
3.
Armstrong A, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, et al.
JAMA Dermatol
. 2025 Feb;
PMID: 40009402
Importance: A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument. Objective: To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific...
4.
Perez-Chada L, Gondo G, Grant C, Woodbury M, Kucharik A, Armstrong A, et al.
J Invest Dermatol
. 2025 Jan;
PMID: 39864735
No abstract available.
5.
Peterson H, Miao K, Huang M, Armstrong A
J Clin Aesthet Dermatol
. 2025 Jan;
18(1):18-19.
PMID: 39830822
No abstract available.
6.
Gorelick J, Nguyen A, Schneider S, Martel B, Madsen D, Armstrong A
Am J Clin Dermatol
. 2025 Jan;
26(2):199-211.
PMID: 39820896
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including...
7.
Kingston P, Peterson H, Lee K, Huang M, Yee D, Korouri E, et al.
J Eur Acad Dermatol Venereol
. 2025 Jan;
PMID: 39775852
No abstract available.
8.
Guo L, Kircik L, Armstrong A
J Drugs Dermatol
. 2025 Jan;
24(1):491722s4-491722s14.
PMID: 39761151
Obesity is a metabolic disease that is marked by excessive fat accumulation and is objectively defined as a body mass index (BMI) ≥30 kg/m2. Obesity is associated with several other...
9.
Tada Y, Armstrong A, Imafuku S, Okubo Y, Morita A, Zhong Y, et al.
J Dermatol
. 2024 Dec;
52(2):353-358.
PMID: 39641509
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in Japan for adult patients with plaque, generalized pustular, or erythrodermic psoriasis. POETYK PSO-4 (NCT03924427), an open-label, single-arm, phase...
10.
Datta-Mannan A, Moser B, Xu W, Jackson K, Witcher J, Armstrong A, et al.
Clin Ther
. 2024 Dec;
47(1):55-61.
PMID: 39638723
Purpose: Lebrikizumab is a novel, high-affinity immunoglobulin G4 monoclonal antibody that targets interleukin-13, a central mediator in atopic dermatitis (AD). In previous studies in patients with moderate-to-severe AD, lebrikizumab, administered...